Day: March 8, 2023

Company to Host Conference Call Today at 8:30 a.m. ET BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update “In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperidone as a potentially transformative treatment for those patients with negative symptoms of...

2023 Free Cash Flow Allocation 2023 Free Cash Flow AllocationCALGARY, Alberta, March 08, 2023 (GLOBE NEWSWIRE) — (PIPE – TSX) Pipestone Energy Corp. (“Pipestone” or the “Company”) is pleased to report its fourth quarter and full year 2022 financial and operation results. FOURTH QUARTER 2022 CORPORATE HIGHLIGHTSIn Q4 2022, Pipestone achieved record average quarterly production totaling 33,816 boe/d (30% condensate and crude oil, 42% total liquids), representing a 5% quarterly increase over Q3 2022, and a 18% increase over Q4 2021. The Company’s average annual production for 2022 was 31,090 boe/d (29% condensate, 41% total liquids) within its guidance range of 31,000 boe/d and 33,000 boe/d, representing 26% year-over-year growth in average daily production volumes. Production volumes averaged 34,500 boe/d (30% condensate and...

BROOKINGS, S.D., March 08, 2023 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ – DAKT) today reported results for its fiscal 2023 third quarter which ended January 28, 2023. Q3 FY2023 financial highlights:Record third quarter net sales of $185.0 million, a 32.5 percent increase from the third quarter of fiscal 2022 Product order backlog was $429.1 million(1) compared to backlog of $353.3 million in the year-earlier period Gross profit as a percentage of net sales improved from 16.0 percent to 22.6 percent compared to prior year Operating income was $7.1 million and adjusted operating income(2) was $11.7 million, versus an adjusted operating loss of $5.7 million in the third quarter of fiscal 2022 Overall margin improvements were driven by:Strategic pricing increases; Improved supply chain, production and inventory management;...

Operations drive double-digit increases in key financial measures Company to Host Conference Call Today at 9 a.m. ET MIAMI, March 08, 2023 (GLOBE NEWSWIRE) — International Money Express, Inc. (NASDAQ: IMXI) (“Intermex” or the “Company”), one of the nation’s leading omnichannel money transfer services to Latin America, today reported strong growth for the fourth quarter and full year 2022. With double-digit increases in all of the Company’s full year key financial performance measures, the Company continues its track record of exceptional earnings growth as a public company. Financial performance highlights for the fourth quarter of 2022 compared with the same period last year are:Revenues of $154.4 million, an increase of 21.4%; Net Income of $13.1 million, a decrease of 0.5%; Diluted EPS of $0.35 per share, an increase of 6.1%; Adjusted...

– Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 – – Start up Activities for Phase 2 Trial of TARA-002 in Lymphatic Malformations Underway; Trial Initiation Expected 2H23 – – Cash, Cash Equivalents and Investments of $102.3M as of December 31, 2022 Expected to Fund Operations and Data Milestones into 2025 –    NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the full year and fourth quarter ended December 31, 2022, and provided a business update. “With key data and milestones expected from our clinical programs for TARA-002, including...

Net revenues totaled $500.0 million for the fiscal year Net loss totaled ($59.7) million, or ($1.90) per diluted share, for fiscal year; excluding certain items, non-GAAP net income totaled $7.6 million, or $0.24 per diluted share Balance sheet remains strong, with cash and cash equivalents of $46.6 million and no debt Management provides guidance for fiscal year ending February 3, 2024 FORT WAYNE, Ind., March 08, 2023 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) (or the “Company”) today announced its financial results for the fourth quarter and fiscal year ended January 28, 2023 (“Fiscal 2023”). In this release, Vera Bradley, Inc. or “the Company” refers to the entire enterprise and includes both the Vera Bradley and Pura Vida brands. “Vera Bradley” on a stand-alone basis refers only to the Vera Bradley brand. Fourth...